CONSORTIUM OF PROBIOTICS
The present invention relates to a mixture that simulates a portion of intestinal bacteria and is particularly effective in restoring the bacterial flora of a human host affected by Clostridium difficile (CDI), a sporogenous anaerobic bacterium which can cause diarrhea and colitis with severe complications such as megacolon, intestinal perforation, shock, death. This “consortium” of probiotics can be taken orally in such quantities as to reach the colon.
The standard treatment against Clostridium difficile infection, while effective, does not eliminate completely the high risk of infection, i.e. the reappearance of symptoms and positivity of the toxin in the stool within one month of the end of treatment, due to the persistence of spores or the probability of reinfection.
Therefore, inventors selected some specific probiotic microorganisms authorized by EFSA and created a mixture that simulates a portion of intestinal bacteria and is particularly effective in restoring the bacterial flora of the human host.
The present invention also refers to any food products – be it dietary supplements, drinks, nutraceuticals, foods, functional or medicated food – which contain the following mixture of probiotics: Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Bacillus subtilis, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus rhamnosus, Enterococcus faecium, Streptococcus thermofilus, and at least one suitable excipient and / or additive.
- Dietary supplements;
- Functional or medicated food;
- Nutraceutical food.
- No hospitalisation or medical devices required;
- No laboratory for infusion preparation required;
- Greater safety due to use of validated and certified bacteria;
- Usability by all kinds of patients;
- Greater reproducibility in preventing and / or treating intestinal diseases.